Expected to become a heavyweight therapy, Sorrento innovative pain relief patch approved
Release date: 2018-03-02 Recently, Sorrento Therapeutics and its subsidiary Scilex Pharmaceuticals announced that the US FDA approved the listing of its ZTlido (lidocaine topical system 1.8%) to alleviate the pain symptoms associated with post-herpetic neuralgia. Some analysts believe that this innovative painkiller is expected to become a "blockbuster". Postherpetic neuralgia is a complication caused by herpes zoster that affects nerve fibers and the skin, causing burning pain. Even if the rash and blisters caused by herpes zoster subsided, these pains will continue. The risk of suffering from this painful disease increases with age and primarily affects older people over the age of 60. Unfortunately, there is currently no cure for this disease, and existing treatments can only relieve symptoms. The approved ZTlido is an innovative pain-relieving patch that incorporates 1.8% lidocaine in non-aqueous adhesives to relieve symptoms. According to statistics, the United States issued a total of 100 million lidocaine patches in 2017, indicating that patients have significant medical needs in terms of pain relief. The US FDA report pointed out that the adhesion problem of the patch is the most common quality defect. ZTlido is optimized for this and allows the patch to stay in good contact with the skin within 12 hours of use. ▲The molecular structure of lidocaine (Source: PubChem - NIH) In a clinical trial, ZTlido's adhesion was tested. Of the 54 healthy volunteers, 47 (87%) achieved excellent adhesion scores – they were examined every 3 hours for 12 hours of patching. Examination revealed that the patches were more than 90% bonded and showed no signs of shedding. The remaining 7 volunteers (13%) also had higher adhesion scores, with adhesion rates ranging from 75% to 90%, with only the corners of the patch loose. In another Phase 1 clinical trial, ZTlido achieved superior adhesion compared to the existing one. Officials point out that this bonding technology allows patients to maintain good skin and patch contact and effective delivery of lidocaine while exercising. ▲ Dr. Henry Ji, President and CEO of Sorrento and Scilex (Source: Sorrento Official Website) “The common problem with transdermal/topic patches is that they can't be kept on the skin all the time. We designed ZTlido for this problem. Based on ZTlido's adhesion test results, we believe that ZTlido will be welcomed by doctors and patients. They are in need An effective and effective local pain relief program," said Dr. Henry Ji, President and CEO of Sorrento and Scilex: "We plan to expand the use of ZTlido in other indications, and the platform technology behind ZTlido can be used for other The active drug molecule, or a combination of drug molecules. As ZTlido's new drug marketing application was approved, our team successfully implemented our development plan. Now, we look forward to implementing our marketing and strategic cooperation plan. †It is estimated that ZTlido, after approval, will come to the patient later this year. We look forward to the early arrival of this day so that more patients can be relieved from the pain. Reference materials: [1] Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlidoTM (lidocaine topical system) 1.8% for PHN Pain [2] Sorrento Therapeutics Official Website [3] Postherpetic neuralgia – Mayo Clinic Source: WuXi PharmaTech
Orthopedic external fixation system
The screw orthopedic is inserted into the bone near the fracture, and the fracture is fixed with an external fixator assembled by a chuck and a nail rod.
Indications
open fracture, nonunion, closed fracture with extensive soft tissue injury, fracture with multiple trauma, osteotomy and correction.
The use of orthopaedic external fixators is currently a superior fracture fixation technique, filling the gap between cast and internal fixation. At the same time, orthopedic external fixator has the characteristics of simple fixation method, stable, reliable and effective, and does not limit the joint movement, can be early ambulation advantages. It can reduce the time for the operator and is more friendly to the user. The external fixator was used together with the bone traction needle. In terms of the classification of orthopedic external fixators, it is mainly divided into four types: orthofix type external fixation, ilizarov type external fixation, ao synthes type external fixation,combined external fixator and common external fixators.
The external fixators in orthopaedics was used for reduction (shortening and overlapping displacement were corrected first, then lateral and angular displacement were corrected, and finally rotational and separation displacement were corrected; If closed reduction is difficult, open reduction can be considered, but the separation of soft tissue and peeling of periosteum should be minimized.
The selection of the insertion site.According to the anatomical characteristics of the soft tissue at the insertion plane, the important nerves, vessels and tendons should be avoided; The ideal entry point is the part of the bone close to the subcutaneous, in a word, generally choose the skin and bone between the muscle soft tissue is the weakest point into the needle. The installation shall facilitate observation and control of soft tissue damage, and permit any surgery that may be required, such as repair and reconstruction, dressing change, skin grafting, or bone grafting." According to the location of the bone, different diameters of the threaded needle were selected. Removal was performed after completion of late treatment.
Orthopedic External Fixator,Orthopedic Fixator,External Fixation,External Fixator Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com
